• World - North America
  • Updated: March 23, 2021

AstraZeneca To Reveal More COVID-19 Trial Data Following Alarm Raised Over Recent Misleading Results

AstraZeneca To Reveal More COVID-19 Trial Data Following Ala

AstraZeneca has said that it would publish more data on its American clinical trial "within 48 hours" after the monitoring board monitoring the study warned US authorities that results released by the company on Monday were misleading.

The US National Institute of Allergy and Infectious Diseases (NIAID) was notified by the independent monitoring board that it was "concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial".

Speaking on Tuesday, the NIAID said, "The DSMB (the safety monitoring board) expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data."

Responding, AstraZeneca stated that the published results were based on "pre-specified interim analysis" of data up to February 17. 

The AstraZeneca Covid-19 vaccine

"We have reviewed the preliminary assessment of the primary analysis and the results were consistent with the interim analysis", it said. "We will immediately engage with the independent data safety monitoring board (DSMB) to share our primary analysis with the most up-to-date efficacy data.

"We intend to issue results of the primary analysis within 48 hours."

READ ALSO: President Moon Gets AstraZeneca Vaccine Shot Ahead Of G-7 Summit

The trial showed that the AstraZeneca vaccine was 79 percent effective at stopping symptomatic COVID-19 and 100 percent effective at preventing people from falling seriously ill.

It also revealed that there were no major issues relating to blood clots - something that has been of major concern to some regulators in Europe.

Related Topics

Join our Telegram platform to get news update Join Now

0 Comment(s)

See this post in...


We have selected third parties to use cookies for technical purposes as specified in the Cookie Policy. Use the “Accept All” button to consent or “Customize” button to set your cookie tracking settings